PetCaseFinder

Peer-reviewed veterinary case report

Genetic cause of mild mucopolysaccharidosis in Golden Retrievers

By Faller, Kiterie M E et al.·Published in Journal of veterinary internal medicine·2020·School of Veterinary Medicine, United Kingdom·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: A deletion of IDUA exon 10 in a family of Golden Retriever dogs with an attenuated form of mucopolysaccharidosis type I.

Species:
dog
Skin & coatDogs

Plain-English summary

Two Golden Retriever siblings were diagnosed with a rare genetic disorder called mucopolysaccharidosis type I (MPS-I), which caused various health issues including physical deformities and heart problems. They showed symptoms similar to a milder form of the disease seen in humans and had high levels of certain substances in their urine. Genetic testing revealed a specific mutation in their DNA, and treatment with a medication called pentosan polysulfate helped manage their symptoms for a while. Unfortunately, one of the dogs had to be euthanized at 4.5 years old due to the progression of the disease.

People also search for: Golden Retriever mucopolysaccharidosis symptoms · dog heart problems treatment · pentosan polysulfate for dogs

Abstract

BACKGROUND: Mucopolysaccharidosis type I (MPS-I) is a lysosomal storage disorder caused by a deficiency of the enzyme α-l-iduronidase, leading to accumulation of undegraded dermatan and heparan sulfates in the cells and secondary multiorgan dysfunction. In humans, depending upon the nature of the underlying mutation(s) in the IDUA gene, the condition presents with a spectrum of clinical severity. OBJECTIVES: To characterize the clinical and biochemical phenotypes, and the genotype of a family of Golden Retriever dogs. ANIMALS: Two affected siblings and 11 related dogs. METHODS: Family study. Urine metabolic screening and leucocyte lysosomal enzyme activity assays were performed for biochemical characterization. Whole genome sequencing was used to identify the causal mutation. RESULTS: The clinical signs shown by the proband resemble the human attenuated form of the disease, with a dysmorphic appearance, musculoskeletal, ocular and cardiac defects, and survival to adulthood. Urinary metabolic studies identified high levels of dermatan sulfate, heparan sulfate, and heparin. Lysosomal enzyme activities demonstrated deficiency in α-l-iduronidase activity in leucocytes. Genome sequencing revealed a novel homozygous deletion of 287 bp resulting in full deletion of exon 10 of the IDUA gene (NC_006585.3(NM_001313883.1):c.1400-76_1521+89del). Treatment with pentosan polyphosphate improved the clinical signs until euthanasia at 4.5 years. CONCLUSION AND CLINICAL IMPORTANCE: Analysis of the genotype/phenotype correlation in this dog family suggests that dogs with MPS-I could have a less severe phenotype than humans, even in the presence of severe mutations. Treatment with pentosan polyphosphate should be considered in dogs with MPS-I.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32785987/